摘要
目的研究CEA、CA125、CA199联合检测在肺癌诊断中的应用价值,旨在为临床肺癌的早期发现及诊断提供一种快捷而又简单的方法。方法收集2013年1月至2014年10月邢台市人民医院呼吸内科、肿瘤内科和肿瘤外科收治的住院患者338例,其中肺癌患者236例,肺部良性疾病患者102例,50例门诊健康体检者作为健康对照,检测其血清中CEA、CA125、CA199的水平。结果血清CEA、CA199和CA125水平,肺癌组显著高于肺部良性疾病组和健康体检组。CA125诊断肺癌的灵敏度最高,特异度最低,三项联检的灵敏度显著高于任何各单项。结论 CEA,CA125和CA199可作为肺部良、恶性疾病的鉴别指标。单项肿瘤标志物诊断肺癌的灵敏度较低,三项联合检查能有效提高肺癌诊断的灵敏度,但特异度会相应降低。
Objective To investigate the value of combined detection of CEA, CA125 and CA199 in the diagnosis of lung cancer to provide a quick and simple method for early diagnosis of lung cancer. Methods A total of 388 patients including 236 cases of lung cancer and 102 cases of benign lung disease,and 50 healthy controls were involved in this study. The serum tumor markers CEA, CA125 and CA199 were detected. Results The serum levels of CEA, CA125 and CA199 in lung cancer group were significantly higher than that of lung benign disease group and healthy control group. Compared with CEA and CA199, CA125 has the highest sensitivity and the lowest specificity for lung cancer diagnosis. The sensitivity of combined detection of serum CEA,CA125 and CA199 for lung cancer diagnosis was higher than any individual tumor markers. Conclusion The serum CEA, CA125 and CA199 can be used for distinguishing lung cancer and lung benign disease. The combined detection of serum CEA, CA125 and CA199 can improve the sensitivity effectively for lung cancer diagnosis, while the specificity decrease accordingly.
出处
《标记免疫分析与临床》
CAS
2016年第6期668-671,共4页
Labeled Immunoassays and Clinical Medicine
